Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials-Reference-Cited by-同舟云学术

Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials

Published:2018-11-15 Issue:10 Volume:198 Page:1268-1278
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Martinez Fernando J.¹,Rabe Klaus F.²,Calverley Peter M. A.³,Fabbri Leonardo M.⁴⁵,Sethi Sanjay⁶,Pizzichini Emilio⁷,McIvor Andrew⁸,Anzueto Antonio⁹,Alagappan Vijay K. T.¹⁰,Siddiqui Shahid¹⁰,Reisner Colin¹⁰,Zetterstrand Sofia¹¹,Román Jonas¹¹,Purkayastha Debasree¹²,Bagul Nitin¹³,Rennard Stephen I.¹⁴¹⁵

Affiliation:

1. Weill Cornell Medicine, New York, New York

2. LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

3. Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

4. Department of Clinical Medicine, University of Ferrara, Ferrara, Italy

5. COPD Center, Sahlgrenska University Hospital, Gothenburg, Sweden

6. University at Buffalo, State University of New York, Buffalo, New York

7. Universidade Federal de Santa Catarina, Santa Catarina, Brazil

8. McMaster University, Firestone Institute for Respiratory Health, St. Joseph’s Healthcare, Hamilton, Ontario, Canada

9. University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, Texas

10. AstraZeneca, Gaithersburg, Maryland

11. AstraZeneca, Gothenburg, Sweden

12. PHASTAR Corporation, Manchester, United Kingdom

13. Takeda Development Centre Europe Ltd., London, United Kingdom

14. University of Nebraska Medical Center, Omaha, Nebraska; and

15. Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201712-2493OC

Reference28 articles.

1. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

2. Defining the “Frequent Exacerbator” Phenotype in COPD

3. Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease “Super Exacerbators”

4. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial

5. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eosinophils and COPD;COPD in the 21st Century;2024-03-01

2. Differential response to roflumilast in patients with chronic obstructive pulmonary disease: real-world evidence;Journal of Thoracic Disease;2024-02

3. Serum IL-8 as a Determinant of Response to Phosphodiesterase-4 Inhibition in Chronic Obstructive Pulmonary Disease;American Journal of Respiratory and Critical Care Medicine;2023-09-01

4. The Ongoing Quest for Predictive Biomarkers in Chronic Obstructive Pulmonary Disease;American Journal of Respiratory and Critical Care Medicine;2023-09-01

5. Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook;American Journal of Respiratory and Critical Care Medicine;2023-08-15